NCT02838121View on ClinicalTrials.gov

Prevention of Periprosthetic Bone Loss After Total Hip Replacement by Annual Bisphosphonate Therapy

PHASE3CompletedINTERVENTIONAL

Enrollment

62

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2013

Study Completion Date

June 30, 2016

Conditions

Prevention of BMD Loss After THRSerum Markers of Bone TurnoverFunctional Outcomes

Interventions

DRUG

Aclasta

Aclasta once annually for 2 years

DRUG

Placebo

No IV aclasta

Trial Locations (1)

333

Chang Gung Memorial Hospital, Kweishan

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Novartis

INDUSTRY

lead

Mel Shiuann-Sheng Lee

OTHER